Unique Discovery Platform


  • Platform of patient tumor derived anticancer vaccines is owned by Precision Biologics
  • Patents for antibodies cover broad therapeutic and diagnostic utility
  • Ability to develop future, novel products and discover novel targets is unhindered
  • Freedom to operate
  • 7 patents issued and 6 pending

“Our monoclonal antibodies have the ability to act as a companion diagnostic platform to our therapeutic program by recognizing the tumor specific antigen that our therapeutic antibody targets and determine which patients are a candidate to receive treatment.”

Philip M Arlen, MD

Chief Executive Officer